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Background: Medulloblastoma (MB) is the most common malignant brain tumor in childhood with a 5-year survival of
approximately 60%. We have recently shown that treatment of human MB cells with 5-aza-2’-deoxycytidine (5-aza-dC)
reduces the clonogenic survival significantly. Here, we tested combinatorial effects of 5-aza-dC with other epigenetic
(valproic acid, SAHA) and differentiation-inducing drugs (resveratrol, abacavir, retinoic acid) on human MB cells in vitro
to intensify the antitumor therapy further.
Methods: Three human MB cell lines were treated with 5-aza-dC alone or in combination for three or six days.
Metabolic activity was measured by WST-1 assay. To determine long-term reproductive survival, clonogenic assays were
performed. Induction of DNA double-strand break (DSB) repair was measured by γH2AX assay.
Results: The applied single drugs, except for ATRA, reduced the metabolic activity dose-dependently in all MB cell lines.
Longer treatment times enhanced the reduction of metabolic activity by 5-aza-dC. Combinatorial treatments showed
differential, cell line-dependent responses indicating an important impact of the genetic background. 5-Aza-dC together
with resveratrol was found to exert the most significant inhibitory effects on metabolic activity in all cell lines. 5-aza-dC
alone reduced the clonogenicity of MB cells significantly and induced DSB with no further changes after adjuvant
administration of resveratrol.
Conclusion: The observed significant decrease in metabolic activity by combinatorial treatment of MB cells with 5-aza-dC
and resveratrol does not translate into long-term reproductive survival deficiency in vitro. Further studies in animal models
are needed to clarify the resveratrol-mediated anticancer mechanisms in vivo.
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Medulloblastoma (MB) is the most common malignant
brain tumor in childhood and accounts for 20% of such
entities. It arises during embryonic development from
neural precursor cells in the precerebellum or the dorsal
brain stem [1]. It is widely believed that genetic, gene
regulatory, or epigenetic abnormalities give rise to tumor
initiation and inhibit normal neuronal or glial differenti-
ation in neural stem cells [2]. MB standard therapy in-
cludes primary tumor resection followed by irradiation
and/or chemotherapy. At the moment, therapy stratifica-
tion depends on tumor histology, metastasis stage, and* Correspondence: Ina.patties@medizin.uni-leipzig.de
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reproduction in any medium, provided the orpatient age. Patients belonging to the high-risk group
and such with metastases receive a more intensive con-
comitant chemoradiotherapy compared to low-risk pa-
tients. Infants below 18 months do not obtain radiation
therapy to avoid radiation-related adverse late effects,
like neurocognitive and psychomotoric deficits, but
receive a highly aggressive chemotherapy. With overall
5-year survival rates of approximately 60%, an improved
antitumor strategy is urgently needed to further enhance
the outcome of the moderate- and high-risk patients
(90% of all MB patients). Especially in younger children,
a reduction of treatment-induced adverse effects, by
applying less toxic agents, is an ambitious aim in MB
therapy optimization.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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promoter methylation, which are observed in most MBs
(70–90%), lead to silenced tumor suppressor genes
(TSG) and are responsible for the lack of cell cycle arrest
and apoptosis in tumor cells [2]. Hence, the application
of epigenetic modulators in the treatment of MB might
be a suitable approach to improve the standard therapy.
Methyltransferase inhibitors like 5-aza-2’-deoxycytidine
(5-aza-dC, decitabine) and histone deacetylase inhi-
bitors (HDACi) like valproic acid (VPA) or SAHA are
approved for the therapy of other diseases such as
myelodysplastic syndromes, neurological disorders, or
T-cell lymphoma. Application of epigenetic drugs in
leukemia and carcinomas is currently tested in clinical
studies. In addition, the low differentiation stage of MB
cells constitutes also an attractive approach for MB ther-
apy. The usage of differentiation-inducing drugs may in-
duce neuronal or glial maturation in tumor cells and,
therefore, eliminate their cancer-causing abilities. For
instance, all-trans retinoic acid (ATRA) has already
been used in differentiation therapy of leukemia patients.
In vitro experiments with abacavir and resveratrol
exhibited the drug-mediated induction of a more diffe-
rentiated cell phenotype in MB cell lines [3-5]. Combi-
nation of nucleoside analogs like 5-aza-dC with HDACi
might result in amplified effects as HDACi have been
shown to suppress the alien nucleotide removal [6]. Also,
induction of differentiation might work much more success-
fully after reactivation of beforehand silenced differentiation-
relevant genes [7].
In this study, we tested single and combinatorial ef-
fects of 5-aza-dC with other epigenetic drugs (VPA,
SAHA) or differentiation inducers (resveratrol, abacavir,
ATRA), as detailed below, on the metabolic activity and
reproductive survival of human MB cell lines.
5-Aza-dC, a cytidine analog and methyltransferase in-
hibitor, is approved by the U.S. Food and Drug Administra-
tion (FDA) for the treatment of myelodysplastic syndrome
since 2006. 5-Aza-dC is known to reactivate silenced TSG
by demethylation of their promoter regions in MB and
other tumor cells after incorporation into the DNA during
the replication process [8-10]. DNA-integrated 5-aza-dC
traps de novo methyltransferases (DNMT) and induces
DNA damage including double-strand breaks (DSB)
[11,12]. We have recently shown that 5-aza-dC treatment
of human MB cells reduces their vitality, proliferation rate,
and clonogenic survival significantly [8]. Others have de-
scribed similar effects in leukemia and lung cancer cell
lines [13,14].
VPA, an HDACi, has already been established in the
treatment of epilepsy and depression, and clinical trials
for its application in HIV and cancer patients are on-
going. VPA leads to hyperacetylation of histone proteins
resulting in activation of cell cycle arrest and apoptosis inhuman MB cells [15]. In xenograft MB mouse models, it
was shown that VPA alone reduces tumor growth and
prolonges survival [16]. It was also reported that combina-
torial treatment with 5-aza-dC and VPA is able to diminish
tumor initiation in a Ptch-deficient MB mouse model [17].
SAHA (vorinostat, Zolinza™) is the first HDACi ap-
proved by the FDA for cancer treatment. SAHA directly
interacts with the catalytic domain of histone deacetylases
[18]. As a result, gene promoter-bound histones stay
hyperacetylated and facilitate the selective transcription of
genes [19]. Additionally, SAHA exerts chemosensitizing
effects in oral squamous cell carcinoma and medulloblas-
toma cells [20,21].
Abacavir, a 2-deoxyguanine analog, is approved for
HIV and AIDS therapy in the EU since 1999. Two ways
of an abacavir-mediated reduction of telomerase activity
are reported: 1) indirect, by incorporation into the DNA
strand which leads to polymerization stop [22], and 2)
direct, by downregulation of hTERT (human gene for
telomerase reverse transcriptase) mRNA transcription
[3]. In recent years, abacavir attracted attention for can-
cer therapy for its ability to inhibit telomerase activity,
which is known to be overexpressed in the vast majority
of cancers [23]. Also in 70% of MBs, telomerase activity
is enhanced in contrast to normal cerebellum [24]. It
was previously shown that treatment of human MB cell
lines with abacavir results in proliferation inhibition and
neuronal differentiation [3].
ATRA is the prototype of differentiation therapy in
cancer cells and, therefore, it is approved for treatment
of acute promyelocytic leukemia (APL) in the EU since
1996. Inhibition of proliferation and induction of apop-
tosis and differentiation have been observed in many
tumor cells including MB cells after treatment with
ATRA [25-30].
Resveratrol, a plant polyphenol, is described to exhibit
tumor-preventive as well as anticancer effects dependent
on concentration, cell type, and microenvironment
[31-33]. In MB cells, resveratrol has been shown to in-
duce cell cycle arrest, apoptosis, and/or neuronal diffe-
rentiation [4,5,34].
In this study, we show that the applied single media-
tors, except for ATRA, reduce the metabolic activity in
all MB cell lines. In combinatorial treatments with the
epigenetic modifier 5-aza-dC, resveratrol reveals the
strongest decrease in metabolic activity, but it can not




5-Aza-2’deoxycytidine (decitabine, trade name DacogenW),
all-trans retinoic acid (ATRA), resveratrol, and valproic
acid were purchased from Sigma-Aldrich (Munich,
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GlaxoSmithKline (Hamburg, Germany) and suberoy-
lanilide hydroxamic acid (SAHA, vorinostat, trade name
ZolinzaW) from MSD (Haar, Germany). Stock solutions
were prepared as follows and stored at - 20°C: 10 mM
5-aza-dC in PBS; 500 μM ATRA in 10% ethanol
(stored at - 80°C); 500 μM resveratrol in 1% ethanol;
1 M valproic acid in PBS; 100 mM abacavir in PBS;
100 μM SAHA in 0.25% DMSO. Further work solu-
tions were made in PBS and administered in equal di-
lutions to the cell medium. To exclude effects based
on ethanol or DMSO applications, appropriate controls
were implemented.
Cell lines and cell culture
The human MB cell line MEB-Med8a was kindly provided
by Prof. T. Pietsch (Department of Neuropathology, Uni-
versity of Bonn Medical Centre, Bonn, Germany). The
MB cell lines D283-Med and DAOY were purchased from
ATCC cell biology collection (Manassas VA, USA). D283-
Med and DAOY were maintained in MEM (Sigma-
Aldrich, Munich, Germany) including 2 mM L-glutamine
(Biochrom, Berlin, Germany), MEB-Med8a in DMEM
with 4.5 g glucose (Lonza, Basel, Switzerland), all sup-
plemented with 10% FCS (PAA, Yeovil, Somerset, UK),
100 U/ml penicillin, and 100 μg/ml streptomycin
(Biochrom, Berlin, Germany) at 37°C and 5% CO2 unless
otherwise noted.
Metabolic activity
To examine metabolic activity, cells were seeded in trip-
licates in 96-well plates, and after 24 h cells were grown
with or without the modulator for three or, in case of
5-aza-dC, for three and six days. Combinatorial treat-
ments were executed with/without 3 μM (D283-Med) or
5 μM (DAOY, MEB-Med8a) 5-aza-dC and the second
drug (concentrations listed in Table 1). After incubation,
medium was discarded, and cells were incubated with
normal medium including 10% WST-1 reagent (Roche,
Basel, Switzerland) for 1–2 h. Metabolically active cells
have the ability to metabolize the tetrazolium salt WST-1
into a formazan dye. The amount of formed formazanTable 1 Concentrations for the combinatorial treatment
with 5-aza-dC
Modulator D283-Med DAOY MEB-Med8a
5-Aza-dC 3 μM 5 μM 5 μM
VPA 0.77 mM 0.77 mM 0.77 mM
SAHA 0.16 μM 0.16 μM 0.16 μM
Abacavir 0.11 mM 0.11 mM 0.11 mM
Retinoic acid 0.25 μM 0.25 μM 0.25 μM
Resveratrol 15 μM 15 μM 40 μMdye directly correlates with the number of viable cells.
Measuring the formazan dye extinction at 450 nm wave
length relative to medium control corresponds to the
metabolic activity of the viable cells. IC 30 values were
calculated by generating an exponential or linear trend
using Microsoft Excel 2003 software.Clonogenic survival
For clonogenic assays, cells were treated with/without
3 μM (D283-Med) or 5 μM (DAOY, MEB-Med8a) 5-aza-dC
in cell culture flasks for three days. Subsequently, medium
was renewed and supplemented with 5-aza-dC and 15 μM
(D283-Med, DAOY) or 40 μM Resveratrol (MEB-Med8).
After three days, cells were counted, seeded at three differ-
ent cell densities in duplicates in 6-well cell culture plates,
and normal medium without mediators was added. Ten
to 14 days later, colonies were washed with PBS, fixed
with ice-cold ethanol/acetone (1 : 1) for 10 min, stained
with Giemsa solution (1 : 1 with distilled water) for 5
min, and washed with distilled water. Colonies with >
50 cells were counted indicating plating efficiency (PE).
The ratio between PE of treated cells and PE of un-
treated cells represented the surviving fraction (SF) of
clonogenic cells.Statistics
Statistic analyses of were performed using the paramet-
ric, one-way, and paired Student’s t-test with Microsoft
Excel 2003 software. P-values ≤ 0.05 (*) were considered
as statistically significant and p-values ≤ 0.001 (**) as
highly statistically significant.
Detailed drug interaction analyses regarding synergis-
tic or additive effects were conducted using the Bliss
independence (BI) model which is based on the non-
interaction theory. The BI model compares the estimates
of the combined effects calculated on the individual drug
effects with those obtained from the experiment. There-
fore, the following equation was used: Ei = EA × EB,
where Ei is the estimated amount of metabolic activity of
the theoretical combination of substance A and B, and
EA and EB are the experimental rates of metabolic acti-
vity of each drug alone. The interaction of both is de-
scribed by the difference ΔE between the estimated and
the observed rates of metabolic activity ΔE = Eestimated −
Eobserved [35]. The non-parametric approach described by
Prichard et al. was modified and used to calculate statis-
tical significance of synergism. In each of the three inde-
pendent experiments, the observed rates of metabolic
activity were subtracted from the predicted values, and
the average difference of each experiment was calcu-
lated. Statistically significant synergy was claimed when
the average difference as well as its 95% confidence
interval was positive [36].
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To determine submaximal concentrations for the inhib-
ition of the metabolic activity of MB cells, we performed
incubation experiments with the single drugs. The mean
drug concentration of the three examined cell lines
which inhibits the metabolic activity by 30% (IC30) was
chosen for combination treatments with 5-aza-dC for
three days (Table 1). The long-time reproductive cell
survival of the combination showing the most promising
results in metabolic inhibition was investigated and in-
duction of DSB as a potential mechanism for cell death
was evaluated.
Effects on metabolic activity (WST-1 assay)
After treatment with 5-aza-dC, we observed an enhanced
reduction of metabolic activity in all cell lines treated for
six days versus three days (Figure 1). As 5-aza-dC incor-
poration depends on cell cycle progression and prolifera-
tion frequency [10], the longer incubation period allows
more 5-aza-dC to be incorporated into DNA. Surprisingly,
5-aza-dC exhibited the strongest inhibitory effect in slowly
proliferating D283-Med cells, whereas DAOY cells, show-
ing the shortest replication time, were much more resist-
ant. Although 5-aza-dC-induced inhibition was stronger
after 6 versus 3 days of treatment, leading to a total loss of
metabolic activity in D283-Med and MEB-Med8a, about
20% of metabolic activity remained in DAOY cells. The
relative 5-aza-dC resistance of DAOY cells versus MEB-
Med8a and D283-Med cells in mortality and cell growth
arrest has already been shown by our workgroup [8]. This
indicates that, beside the incubation period-dependent
incorporation rate, other mechanisms, like repair efficiency
or DNMT activity, are involved in 5-aza-dC-induced
cytotoxicity.
VPA led to a strong dose-dependent decrease of meta-
bolic activity in all three MB cell lines (Figure 2a). The in-
dividual VPA concentrations leading to 30% inhibition
(IC 30) were between 0.27 mM (MEB-Med8a) and 0.9 mM
(D283-Med) after VPA treatment for three days. AfterFigure 1 Time- and dose-dependent inhibition of metabolic activity b
measured by WST-1 assay after 5-aza-dC treatment for three or six days. Ra
experiment are shown as means ± SEM of triplicate samples.combinatorial treatment with 5-aza-dC, additive effects
on the reduction of metabolic activity in two cell lines
(DAOY, D283-Med) with a significant synergistic response
in DAOY cells were observed. This is in accordance with
data obtained from Yang et al. showing synergistic effects
on inhibition of cell growth and induction of apoptosis in
human leukemic cell lines [37]. In contrast, combined
5-aza-dC/VPA treatment of MEB-Med8a cells revealed a
significant increase of 25% in metabolic activity compared
to 5-aza-dC monotherapy (Figure 3a). Conceivably in
MEB-Med8a cells, VPA mainly induces G1 arrest by in-
duction of p21 expression [15] and, therefore, prevents
cytotoxic 5-aza-dC incorporation into the DNA molecule.
Also, SAHA induced a concentration-dependent de-
crease of metabolic activity (Figure 2b). The IC 30 values
were 60 nM ‒ 260 nM (MEB-Med8a, D283-Med). After
simultaneous treatment with 5-aza-dC, the metabolic
activity of D283-Med and DAOY cells was only slightly
reduced, compared to 5-aza-dC alone. Similarly to
5-aza-dC/VPA treatment response, MEB-Meb8a cells
exhibited a significant enhancement of metabolic activity
after combined treatment with SAHA (Figure 3b). Cor-
responding to these cell line-specific findings, differential
results have also been published showing minor effects
in colon carcinoma cells, but significantly enhanced cell
death in ovarian cancer and leukemia cells after com-
binatorial 5-aza-dC/SAHA treatment [38-40].
Treatment of MB cells with abacavir resulted in a dose-
dependent reduction of metabolic activity (Figure 2c).
Thereby, D283-Med revealed to be the most resistant
among the examined cell lines showing an IC 30 value of
340 μM, whereas MEB-Med8a and DAOY cells exhibited
IC 30 values of 70 μM and 150 μM. The higher resistance
is possibly due to a higher expression of human telomerase
reverse transcriptase (hTERT) in D283-Med cells com-
pared to DAOY cells [3,24]. Applying higher abacavir con-
centrations (350 μM to 750 μM, treated for 24 to 96 h),
Rossi et al. reported that abacavir induces enhanced mor-
tality in D283-Med cells, but differentiation and growth ar-
rest in DAOY cells [3]. We found here that simultaneousy 5-aza-dC. Metabolic activity of three medulloblastoma cell lines was
w values were normalized to untreated control. Data from one
Figure 2 Dose-dependent inhibition of metabolic activity by valproic acid, SAHA, abacavir, retinoic acid, and resveratrol. Metabolic
activity of three medulloblastoma cell lines was measured by WST-1 assay after treatment with the indicated modulators for three days. Raw
values were normalized to untreated control. Data are presented as mean ± SEM from at least three independent experiments done in triplicates.
IC 30 values, depicted as black lines, indicate concentrations with 30-percent inhibition of metabolic activity.
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two MB cell lines (DAOY, D283-Med) in metabolic activ-
ity (Figure 3c). This is the first time showing intensifying
in vitro effects of an epigenetic modifier and a telomerase
inhibitor on metabolic activity of tumor cells.Figure 3 Combinatorial effects of 5-aza-dC with valproic acid, SAHA,
Three medulloblastoma cell lines were treated with 5-aza-dC and/or in
and WST-1 test perfomed. Treated samples were normalized to the un
experiments done in triplicates. The statistical significance of difference
asterisks: *, p ≤ 0.05; **, p ≤ 0.001.Retinoic acid treatment induced differential, cell line-
specific effects: MEB-Med8a cells showed no response to
ATRA; DAOY cells exhibited only a moderate reduction
of metabolic activity with a maximum of 30%; and in
D283-Med cells, a dose-dependent reduction of metabolicabacavir, retinoic acid, and resveratrol on metabolic activity.
dicated drugs for three days at concentrations listed in Table 1
treated control. Data show means ± SEM of at least three
s between 5-aza-dC and combinatorial treatments is indicated by
Figure 4 Clonogenicity after combined treatment with 5-aza-dC
and resveratrol. Clonogenic survival of three medulloblastoma cell
lines was determined after treatment with 5-aza-dC and/or
resveratrol relative to the untreated control. Surviving fractions from
at least two separate experiments done in sextuplicates are depicted
and mean values ± SEM are presented. Statistical significance of
treated versus untreated (control) is indicated by asterisks: *, p ≤ 0.05.
Differences between 5-aza-dC and combinatorial treatments are
depicted as bracket: n.s. non-significant.
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(Figure 2d). This goes along with findings of other groups
[28,30,41]. In the highly sensitive D283-Med cell line, an
ATRA-mediated caspase 3 induction followed by apop-
tosis has been reported [28]. In contrast, DAOY cells
showed only a moderate ATRA-induced enhancement of
caspase 3 expression and apoptosis [30]. The presence of
OTX2 (orthodenticle homeobox 2), a homeobox protein
acting as a transcription factor during brain development,
seems to be necessary for ATRA-induced mortality of
tumor cells. In accordance, enhanced OTX2 protein levels
have been observed in the sensitive D283-Med cells,
whereas the relatively resistant DAOY cells do not express
OTX2 [41]. The combinatorial treatment with 5-aza-dCFigure 5 DSB induction after 5-aza-dC and/or resveratrol treatment. I
assay in three medulloblastoma cell lines after treatment with 5-aza-dC and
untreated cells are represented. One experiment was performed containingrevealed no further effect in the ATRA-sensitive D283-
Med cells but led to a significant increase of metabolic ac-
tivity in DAOY cells compared to 5-aza-dC alone. The
simultaneous treatment of the ATRA-resistant MEB-
Med8a cells showed no 5-aza-dC-dependent effect on the
ATRA responder status (Figure 3d). In contrast, Fu et al.
reported a 5-aza-dC-induced hypomethylation of the
hypermethylated CRABP-II (cellular retinoic acid-
binding protein) gene promoter in ATRA-resistant MB
cells leading to the expression of the afore-silenced
gene. This affects the ATRA transport into the nucleus
and lead to an ATRA-mediated cellular response in
these MB cells [47]. However, the lack of an ATRA re-
sponse in MEB-Med8a after combined treatment with
5-aza-dC indicates that hypermethylation of the CRABP-II
promoter is not responsible for ATRA resistance in this
MB cell line.
As shown in Figure 2e, resveratrol (> 10 μM) led to a
significant concentration-dependent reduction of meta-
bolic activity in all three examined cell lines, possibly by
inhibition of STAT3 (signal transducer and activator of
transcription 3) expression and activity, which results in
irreversible cell cycle arrest or apoptosis [44]. The IC 30
values of 15 μM (D283-Med, DAOY) and 40 μM (MEB-
Med8a) are within the concentrations of 40 μM, ma-
ximal achievable in blood serum after intravenous injec-
tion [42]. The combined administration of resveratrol
and 5-aza-dC showed a significant synergistic inhibition
of 18% (MEB-Med8a), 41% (D283-Med) and 54%
(DAOY) on metabolic activity versus 5-aza-dC alone
(Figure 3e). The sensitive response of the TP53-mutated
DAOY cell line might indicate a speculative role of res-
veratrol in the therapy of highly aggressive and therapy-
resistant TP53-mutated MB tumors. Numerous studies,
regarding the outcome of TP53-mutated MBs, which
represents about 10% of all MBs, showed a 5-year event-
free survival of 0% [43-47]. Interestingly, resveratrol has
been shown to induce apoptosis p53-dependently and
also p53-independently [48,49].nduction of DNA double-strand break repair was measured by γH2AX
/or resveratrol. Numbers of foci per cell less initial number of
at least 50 counted cell nuclei.
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clonogenicity and DSB repair
Our investigations on metabolic activity revealed that
5-aza-dC combined with resveratrol achieve the highest
antitumor response compared to the other tested drugs.
To assess long-time effects, we determined the repro-
ductive cell survival by clonogenic assay after combined
5-aza-dC and resveratrol treatment. 5-Aza-dC alone
resulted in a decrease of surviving clonogenic cells ex-
hibiting surviving fractions (SF) between 0.0014 (DAOY,
D283-Med8) and 0.0023 (MEB-Med8a), similar to our
previously published data [8]. After resveratrol treat-
ment, a significant decline of clonogenic survival was
only observed in MEB-Med8a leading to a SF of 0.022,
whereas, in DAOY and D283-Med, only small effects
were seen (SF(DAOY) = 0.52; SF(D283-Med) = 0.13). The
combinatorial treatment with 5-aza-dC and resveratrol
revealed no overall decline but cell line-specific effects
on clonogenic survival. A resveratrol-mediated en-
hancement of 5-aza-dC-induced clonogenic cell death
was observed in MEB-Med8a and DAOY with a re-
duction by 78% (SF = 0.0005) and 64% (SF = 0.0005)
versus 5-aza-dC alone. In contrast, resveratrol showed
protective effects on clonogenicity of D283-Med cells
represented by a 2.9fold enhancement (SF = 0.0041)
in clonogenic survival of 5-aza-dC-treated cells
(Figure 4).
A common mechanism for the initiation of clonogenic
cell death is the induction of DSB [50]. Therefore, we
measured the DSB indirectly by immune fluorescence
staining of γH2AX repair protein 1 h and 24 h after res-
veratrol treatment. 5-Aza-dC or resveratrol alone caused
the formation of γH2AX foci, although there was no
correlation between initial (1 h) nor residual (24 h) foci
number and surviving fraction. Palii et al. have previ-
ously described the DSB-inducing cytotoxic capabilities
of 5-aza-dC in cervix and colon carcinoma cells [12].
Also, it was shown that resveratrol influences the DSB
repair cascade and, thereby, induces γH2AX foci in
ovarian cancer cells [51]. Adjuvant resveratrol admin-
istration exhibits no further effects on the 5-aza-dC-
induced DSB repair, as no additional foci induction in
MEB-Med8a and DAOY cells was found. Contrary to
this, in D283-Med cells even a decrease of DSB for-
mation was detected (Figure 5) which is going along
with our findings showing an enhancement of clono-
genic survival. Moreover, the resveratrol-mediated in-
duction of base excision repair [52] which is shown to
be p53-dependent [53], might reduce the priorly
DNA-incorporated 5-aza-dC in p53 wild-type D283-
Med cells. Possibly, similar mechanisms are respon-
sible for the protective effects of resveratrol on the
survival of normal cells after chemotherapeutical treat-
ment [54,55].Conclusions
Combination of 5-aza-dC and differentiation-inducing
or epigenetic mediators show promising antitumor ef-
fects on metabolic activity of MB cells. Cell line-specific
results indicate an important impact of the genetic back-
ground, which is known to be extremely variable in
MBs. Further insight in the acting mechanisms, espe-
cially of resveratrol, is needed to evaluate the full poten-
tial in antitumor therapy and to translate the synergistic
effects on short-term metabolic activity into long-term
reproductive survival deficiency.
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